Gartner Blog Network

Showing results for "0":

2 x Life Science Hype Cycles

by Michael Shanler  |  July 29, 2017

While the spring rains drenched the northeastern U.S. and parts of Europe, Jeff, Steve, and I were hard at work authoring, arranging, writing, reviewing,  re-reviewing, re-re-reviewing our content.  After countless cups of coffee, our 2 x hype cycles that cover the life science industry are finally published.  These docs are relevant for CIOs, IT and business […]

Read more »

This Internet of Lab Things – Io(L)T – will be sweet

by Michael Shanler  |  July 9, 2017

An artist friend recently asked me what is this Internet of Things “thing” is.  He’s always been suspicious of modern technology and doesn’t like the idea of technology disrupting his natural humanity.   He read that IoT will change the world and is most concerned that his fridge would soon work against him with Amazon Alexa.  He’s […]

Read more »

A CIO’s 24 Hours of Le Mans

by Michael Shanler  |  June 28, 2017

CIOs are competing in an endurance race.  Winning requires carefully orchestrated activities that rely on technology, team work, precision driving, and a bit of luck.   As in racing, the victorious often win with the slimmest of margins and every single decision along the way can impact an outcome.  It is easy to be lost in […]

Read more »

Hey Ya! Cool Vendors in R&D is out…

by Michael Shanler  |  May 22, 2017

“…Now what’s cooler than bein’ cool? (Ice cold!)…” – André “André 3000” Benjamin from OutKast André 3000″ is the 9th most influential rapper of all time  according to  He’s in an elite class with such influential heavy weights as 2Pac, IceCube and Jay Z.   What I like most about him is his ability to bring […]

Read more »

Hype Cycle for Life Science R&D

by Michael Shanler  |  July 25, 2016

This year, we unveiled a brand new hype cycle, one that is 100% Life Science R&D-focused. “… the moon does not present the same face every day. It waxes, or grows larger, until it becomes a glowing silver-white disk. Then night by night it wanes, or shrinks, to a curved sliver until it vanishes altogether…”  Read more: This […]

Read more »

Hype Cycle for 3D Printing is Out

by Michael Shanler  |  July 22, 2016

People are doing a hell of a lot more than 3D-printing personalized bobble heads and cheap chess pieces.   Granted, there is still a lot of “hype” about the technologies… but many of us  have already experienced the impacts of 3DP without even realizing it. We’ve walked in shoes with 3DP soles. We’ve been driven in […]

Read more »

Mutate the DNA of Pharma Externalization

by Michael Shanler  |  May 12, 2016

Here’s a prediction.  Life Science CxOs that continue to oversimplify “externalized innovation” strategies are in for a career-ending surprise in a few years.   For details, check this out:  Industry Visions: Life Science R&D as a Digital Innovation Orchestration Engine.  A generation ago, before the “patent cliff,” we heard from investment analysts about how “externalized […]

Read more »

R&D Cool Vendor Landscaping

by Michael Shanler  |  May 1, 2016

A few days ago, we released the R&D Cool Vendors list.   Similar to selecting the right plants for our yard, filtering the right technology-based vendors for this report required a fair bit of attention.  We sought vendors that enable “Digital R&D” and innovation strategies that: Operate at the intersection of scientific, laboratory and engineering-related processes; Leverage […]

Read more »

Cool Vendors in Life Science

by Michael Shanler  |  April 18, 2016

Allegra, Benadryl, Sudafed, Flonase, Claritin, Zyrtec, Tavist…. Why mention these drugs at this point in time?   Well…Spring is finally here.    Each season many of us spend some quality time with those little allergy pills…..  using them to try to squint through the annoying blurriness or reduce the itchiness.   We use them to attempt to gain […]

Read more »

Dealing with Electronic Trial Masterphobia…

by Michael Shanler  |  April 5, 2016

There’s an eTMF monster hiding under the bed… Well, not really…but I did recently have a conversation with a pharma R&D CIO (btw- he pre-approved me to blog about this) who mentioned that his clinical and TMF stakeholders were afraid of the consequences of moving away from a hastily implemented, resource-intensive, SP-based solution onto a new […]

Read more »